Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.
Keywords: Pulmonary arterial hypertension; gene therapy; immunity; inflammation; initial combination therapy; macitentan; metabolism; pulmonary arterial denervation; riociguat; selexipag; serotonin..
Copyright© Bentham Science Publishers; For any queries, please email at [email protected].